Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

NCT01769378 · Completed

Last updated 2026-05-28

This clinical trial is testing how the medication dulaglutide compares to a placebo in adults with type 2 diabetes who are also taking sulfonylurea therapy.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 300 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-01 · est. completion 2014-12

Where 31 sites · Argentina, Austria, Croatia, Mexico, Romania, Slovenia, South Africa, United States

What this study is testing ClinicalTrials.gov NCT01769378 ↗

Description as written by the study sponsor.

The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.

Treatments tested

Placebo Drug

Administered SQ
Dulaglutide also known as LY2189265 Drug

Administered SQ
Glimepiride Drug

Administered PO

Main thing measured	Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01769378 ↗